What is ABBV's P/E ratio?

ABBVIE INC (ABBV) currently trades at a P/E ratio of 123.01.

ABBVIE INC reports a Return on Equity (ROE) of -55.04%.

What is ABBV's dividend yield?

ABBVIE INC offers a dividend yield of 2.77%.

What is ABBV's Deepscope Quality Score?

Deepscope rates ABBV's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ABBV?

Deepscope's AI Timing Score for ABBV is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ABBV belong to?

ABBVIE INC is classified under the Healthcare >> Drug Manufacturers - General sector on the NYSE exchange.

หุ้น ABBV (NYSE) | ABBVIE INC – วิเคราะห์โดย Deepscope

Stock Check ข้อมูลอัปเดตรายวัน ที่เวลา 09.30 น.
(Price: 2026-06-30 | FS: 2026-03-31)

ABBV

ABBVIE INC

USD 251.64

-2.67 (-1.05%) Day Change

Watchlist Portfolio Compare Chart

123.01

P/E

-11.02

D/E

-55.0%

ROE

2.7%

ROA

2.77%

Div Yield

-5.12

PEG

ABBVIE INC
TYPE: STOCK
MARKET: NYSE

Compare Watchlist Myport

USD 251.64 Price -2.67 (-1.05%) Day Change	NEWS SCORE: 87

ABBV มีคุณภาพโดยรวมไม่ดี ( คะแนนปัจจัยพื้นฐาน = 46) แต่ จังหวะเข้าซื้อ ...(ล็อกอินเพื่อดู)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio ค่อนข้างสูง
อัตราผลตอบแทนผู้ถือหุ้น (ROE) ค่อนข้างต่ำ
อัตราเร่งของการเติบโตของอัตราผลตอบแทนผู้ถือหุ้น (ROE) ต่ำกว่าเกณฑ์
อัตราการเติบโตของอัตราผลตอบแทนผู้ถือหุ้น (ROE) ในปีก่อน เป็นลบ
อัตราเร่งของการเติบโตของอัตราผลตอบแทนสินทรัพย์ (ROA) ต่ำกว่าเกณฑ์
อัตรากำไรสุทธิ ค่อนข้างต่ำ
อัตราเร่งของการเติบโตของอัตรากำไรสุทธิ ต่ำกว่าเกณฑ์
อัตรากำไรสุทธิในอดีต ค่อนข้างต่ำ

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

ถ้าดูอย่างละเอียดจะพบว่า ปัจจัยทางคุณภาพ ไม่ดี สุขภาพทางการเงิน ไม่ดี และ ประสิทธิภาพการทำกำไร พอใช้ , ...

ปัจจัยทางคุณภาพ

44%

In Recommendations?	Not in any sections
Select Rate	2.08 From 30 days period
Watch Rate	0.08 From 30 days period
News Score	87
Magic Formula Rank by ROA	2779
Magic Formula Rank by ROE	2779
Magic Formula Rank by ROIC	2743
Price	251.64
PBV / Sector	-67.70 / 2.72
Earning Per Share	2.05

PE / Sector	123.01 / 26.03
PEG or PE/Growth / Sector	-5.12 / 0.04
Average 1M Daily Value	1,953.04 M GREAT
Average 1W Daily Value	4,190.06 M GREAT

ปัจจัยทางเทคนิค

85%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

สุขภาพทางการเงิน

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ประสิทธิภาพการทำกำไร

66%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	5.79 / 18.17
NPM Average (%) / Sector	9.93 / 17.77
NPM Change Average (%) / Sector	-24.11 / 93.90
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	2.67 / 8.90
ROA Average (%) / Sector	4.22 / 8.60
ROA Change Average (%) / Sector	-21.45 / 95.12
ROE (%) / Sector	-55.04 / 27.16
ROE Average (%) / Sector	11.29 / 13.13
ROE Change Average (%) / Sector	-30.18 / 97.87
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

ผลตอบแทนต่อผู้ถือหุ้น

12%

Dividend (%) / Sector	2.77 / 2.56
Dividend Average (%) / Sector	3.47 / 3.45
Dividend Change Average (%) / Sector	-7.87 / 5.69

รายละเอียดการจดทะเบียน

Analyze Date	2026-07-01 10:14:46
Symbol	ABBV
Name	ABBVIE INC
Sector	Healthcare >> Drug Manufacturers - General
Market	NYSE
Listed Shares	1,766.79 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	447,616.97 / 256,983.41

ข่าว, ประมาณการ, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400

Phone: 847 932 7900

Website: https://www.abbvie.com

Employees: 57,000

Sector: Healthcare >> Drug Manufacturers - General

Description: AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.